Lab180 Srpski

English

Publications

 

2018

 

  1. Veljkovic N, Zaric B, Djuric I, Obradovic M, Sudar-Milovanovic E, Radak D, Isenovic E. Genetic Markers for Coronary Artery Disease. Medicina (Kaunas). 2018; 54(3):36.
  2. Milivojevic D, Sumonja N, Medic S, Pavic A, Moric I, Vasiljevic B, Senerovic L, Nikodinovic-Runic J. Biofilm-forming ability and infection potential of Pseudomonas aeruginosa strains isolated from animals and humans. Pathogens and disease. 2018; 76(4):fty041.
  3. Stevanović S, Perdih A, Senćanski M, Glišić S, Duarte M, Tomás AM, Sena FV, Sousa FM, Pereira MM, Solmajer T. In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum. Molecules. 2018; 23(4):772. doi: 10.3390/molecules23040772.
  4. Glisic S, Veljkovic V. Chapter 9 - Design of targeting peptides for nanodrugs for treatment of infectious diseases and cancer. Editor(s): Alexandru Mihai Grumezescu, Drug Targeting and Stimuli Sensitive Drug Delivery Systems, William Andrew Publishing. 2018; Pages 343-381. doi: 10.1016/B978-0-12-813689-8.00009-4.
  5. Perovic V, Sumonja N, Marsh L, Radovanovic S, Vukicevic M, Roberts S, Veljkovic N. IDPpi: Protein-Protein Interaction Analyses of Human Intrinsically Disordered Proteins. Scientific Reports. 2018; doi: 10.1038/s41598-018-28815-x.
  6. Paessler S, Huang C, Sencanski M, Veljkovic N, Perovic V, Glisic S, Veljkovic V. Ibuprofen as a template molecule for drug design against Ebola virus. Frontiers in bioscience (Landmark edition). 2018; 23:947-953.
  7. Gemovic B, Sumonja N, Davidovic R, Perovic V, Veljkovic N. Mapping of Protein-Protein Interactions: Web-Based Resources for Revealing Interactomes. Current medicinal chemistry. 2018. DOI: 10.2174/0929867325666180214113704

 

2017

 

  1. Filipović NR, Bjelogrlić SK, Pelliccia S, Jovanović VB, Kojić M, Senćanski M, La Regina G, Silvestri R, Muller CD, Todorović TR. Selenotriapine – An isostere of the most studied thiosemicarbazone with pronounced pro-apoptotic activity, low toxicity and ability to challenge phenotype reprogramming of 3-D mammary adenocarcinoma tumors. Arabian Journal of Chemistry. 2017; doi: 10.1016/j.arabjc.2017.11.017.
  2. Bojic T, Perovic VR, Sencanski M, Glisic S. Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in Chronic Tinnitus. Frontiers in neuroscience. 2017; 11:636.
  3. Perovic V, Gemovic B, Veljkovic V, Glisic S, Veljkovic N. Annotation of the functional impact of coding genetic variants. Biologia Serbica. 2017; 39(1).
  4. Sencanski M, Djordjevic I, Grubisic S. Assessing the Dispersive and Electrostatic Components of the Selenium - Aromatic Interaction Energy by DFT. J Mol Model. 2017; 23(5):162.
  5. Piovesan D, Tabaro F, Micetic I, et al. DisProt 7.0: a major update of the database of disordered proteins. Nucleic Acids Res. 2017; 45(D1):D219-27.
  6. Perovic V, Sumonja N, Gemovic B, Toska E, Roberts SG, Veljkovic N. TRI_tool: a web-tool for prediction of protein-protein interactions in human transcriptional regulation. Bioinformatics. 2017; 33(2):289-91.

 

2016

 

  1. Veljkovic V, Glisic S, Perovic V, Paessler S, Veljkovic N, Nicolson GL. Simple Chemoinformatics Criterion Using Electron Donor-Acceptor Molecular Characteristics for Selection of Antibiotics Against Multi-Drug-Resistant Bacteria. Discoveries 2016; 4(3): e64 DOI: 10.15190/d.2016.11.
  2. Veljkovic V, Veljkovic N, Paessler S, Goeijenbier M, Perovic V, Glisic S, Muller CP. Predicted enhanced human propensity of current avian-like H1N1 swine influenza virus from China. PLoS One. 2016; 11(11):e0165451.
  3. Jiang Y., Oron T., Clarck W.T. et al. An expanded evaluation of protein function prediction methods shows an improvement in accuracy. Genome Biol. 2016;17(1):184.
  4. Vucicevic J, Srdic-Rajic T, Pieroni M, Laurila JM, Perovic V, Tassini S, Azzali E, Costantino G, Glisic S, Agbaba D, Scheinin M, Nikolic K, Radi M, Veljkovic N. A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. Bioorg Med Chem. 2016;24(14):3174-83.
  5. Glisic S, Radosevic D, Perovic V, Sumonja N, Gemovic B, Veljkovic N, Dopsaj M. Role of genetic markers in sport and recreational physical activity. Physical Culture. 2016; 70(1), 5-13.
  6. Jovanovic-Cupic S, Glisic S, Stanojevic M, Nozic D, Petrovic N, Mandusic V, Krajnovic M. The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. Arch Virol. 2016;161(5):1189-98.
  7. Glisic S, Sencanski M, Perovic V, Stevanovic S, García-Sosa AT. Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets. Molecules. 2016; 5;21(5).
  8. Glišić S, Cavanaugh DP, Chittur KK, Sencanski M, Perovic V, Bojić T. Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3. BMC Bioinformatics. 2016; 22;17:139. doi:10.1186/s12859-016- 0988-7.
  9. Srdic-Rajic T, Nikolic K, Cavic M, Djokic I, Gemovic B, Perovic V, Veljkovic N. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. Eur J Pharm Sci. 2016; 1;81:172-80.
  10. Bojic T, Perovic V, Glisic S. In silico therapeutics for neurogenic hypertension and vasovagal syncope. Front. Neurosci. 2016; 9:520. doi: 10.3389/fnins.2015.00520
  11. Filipović NR, Bjelogrlić S, Portalone G, Pelliccia S, Silvestri R, Klisurić O, Senćanski M, Stanković D, Todorović T, Muller CD. Pro-apoptotic and pro-differentiation induction by 8- quinolinecarboxaldehyde selenosemicarbazone and its Co(III) complex in human cancer cell lines. Medicinal Chemistry Communication 2016, doi: 10.1039/C6MD00199H
  12. Fábián B, Senćanski M, Cvijetić I, Jedlovszky P, Horvai G. Dynamics of the Water Molecules at the Intrinsic Liquid Surface as Seen from Molecular Dynamics Simulation and ITIM Analysis. The Journal of Physical Chemistry C 2016; 120(16) doi: 10.1021/acs.jpcc.5b10370
  13. Sencanski M, Došen-Mićović L. Importance of Inter-Residue Interactions in Ligand-Receptor Binding. Chemical Papers 2016; 70(5):1-9

 

2015

 

  1. Veljkovic V, Paessler S, Glisic S, Prljic J, Perovic V, Veljkovic N, Scotch M. Evolution of 2014/15 H3N2 influenza viruses circulating in US: consequences for vaccine effectiveness and possible new pandemic. Front. Microbiol. doi: 10.3389/fmicb.2015.01456
  2. Sencanski M, Došen-Mićović L, Sukalovic V, Kostic-Rajacic S. Theoretical insight into sulfur–aromatic interactions with extension to D2 receptor activation mechanism. Structural Chemistry 08/2015; 26(4). doi:10.1007/s11224-015-0574-z
  3. Filipovic N, Bjelogrlic S, Marinkovic A, Verbic T, Cvijetic I, Sencanski M, Rodic M, Vujcic M, Sladic D, Strikovic Z, Todorovic T, Muller C. Zn(II) complex with 2-quinolinecarboxaldehyde selenosemicarbazone: synthesis, structure, interaction studies with DNA/HSA, molecular docking and caspase-8 and -9 independent apoptose induction. RSC Advances 01/2015; doi:10.1039/C5RA19849F
  4. Sencanski M, Radosevic D, Perovic V, Gemovic B, Stanojevic M, Veljkovic N, Glisic S. Natural productsas promising therapeutics for treatment of influenza disease. Curr Pharm Des. 2015; 21(38):5573-88
  5. Glisic S, Paessler S, Veljkovic N, Perovic VR, Prljic J, Veljkovic V. Improving attrition rates in Ebola virus drug discovery. Expert Opin Drug Discov. 2015; 30:1-8.
  6. Schmier S, Mostafa A, Haarmann T, Bannert N, Ziebuhr J, Veljkovic V, Dietrich U, Pleschka S. In Silico Prediction and Experimental Confirmation of HA Residues Conferring Enhanced Human Receptor Specificity of H5N1 Influenza A Viruses. Sci Rep. 2015; 5:11434.
  7. Veljkovic V, Goeijenbier M, Glisic S, Veljkovic N, Perovic VR, Sencanski M, Branch DR, Paessler S. In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease. F1000Res. 2015; 4:104. doi:10.12688/f1000research.6436.1. eCollection 2015.
  8. Veljkovic N, Vucicevic J, Tassini S, Glisic S, Veljkovic V, Radi M. The preclinical discovery and development of maraviroc for the treatment of HIV. Expert Opin Drug Discov. 2015. doi:10.1517/17460441.2015.1041497.
  9. Veljkovic V, Glisic S, Muller CP, Scotch M, Branch DR, Perovic VR, Sencanski M, Veljkovic N, Colombatti A. In silico analysis suggests interaction between Ebola virus and the extracellular matrix. Frontiers in Microbiology. 2015. 6:135. doi:10.3389/fmicb.2015.00135.
  10. Veljkovic V, Loiseau PM, Figadere B, Glisic S, Veljkovic N, Perovic VR, Cavanaugh DP, Branch DR. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research. 2015. 4:34. doi:10.12688/f1000research.6110.1.
  11. Zivković M, Djurić T, Stojković L, Jovanović I, Končar I, Davidović L, Veljković N, Alavantić D, Stanković A. CXCL16 Haplotypes in Patients with Human Carotid Atherosclerosis: Preliminary Results. J Atheroscler Thromb. 2015. 22(1):10-20.

 

2014

 

  1. Mandic M, Drinovec L, Glisic S, Veljkovic N, Nohr J, Vrecl M. Demonstration of a direct interaction between β2-adrenergic receptor and insulin receptor by BRET and bioinformatics. PLoS One. 9(11):e112664. doi:10.1371/journal.pone.0112664. eCollection 2014.
  2. Veljkovic V , Glisic S, Veljkovic N, Bojic T, Dietrich U, Perovic VR, Colombatti A. Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism. Vaccine. 2014. pii: S0264-410X(14)00933-5.
  3. Vujicic AD, Gemovic B, Veljkovic V, Glisic S, Veljkovic N. Natural autoantibodies in healthy neonatals recognizing a peptide derived from the second conserved region of HIV-1 gp120. Vojnosanit Pregl. 2014. 71(4):352-61.

 

2013

 

  1. Perovic VR, Muller CP, Niman HL, Veljkovic N, Dietrich U, Tosic DD, Glisic S, Veljkovic V. Novel phylogenetic algorithm to monitor human tropism in Egyptian H5N1-HPAIV reveals evolution toward efficient human-to-human transmission. PLoS One. 2013. 26;8(4):e61572.
  2. Maga G, Veljkovic N, Crespan E, Spadari S, Prljic J, Perovic V, Glisic S, Veljkovic V. New in silico and conventional in vitro approaches to advance HIV drug discovery and design. Expert Opin Drug Discov. 2013. 8(1):83-92.
  3. Gemovic B, Perovic V, Glisic S, Veljkovic N. Feature-based classification of amino acid substitutions outside conserved functional protein domains. ScientificWorldJournal. 2013. 17;2013:948617.
  4. Nikolic K, Veljkovic N, Gemovic B, Srdic-Rajic T, Agbaba D. Imidazoline-1 receptor ligands as apoptotic agents: pharmacophore modeling and virtual docking study. Comb Chem High Throughput Screen. 2013. 16(4):298-319.
  5. Veljkovic N, Glisic S, Prljic J, Perovic V, Veljkovic V. Simple and general criterion for "in silico" screening of candidate HIV drugs. Curr Pharm Biotechnol. 2013. 14(5):561-9.
  6. Perovic VR. Novel algorithm for phylogenetic analysis of proteins: application to analysis of the evolution of H5N1 influenza viruses. J Math Chem. 2013. 51(8):2238-55.

 

2012

 

  1. Vergara-Alert J, Argilaguet JM, Busquets N, Ballester M, Martín-Valls GE, Rivas R, López-Soria S, Solanes D, Majó N, Segalés J, Veljkovic V, Rodríguez F, Darji A. Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model. PLoS One. 2012. 7(7):e40524.
  2. Glisic S, Veljkovic N, Jovanovic Cupic S, Vasiljevic N, Prljic J, Gemovic B, Perovic V, Veljkovic V. Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b. Protein J. 2012. 31(2):129-36.
  3. Mancini M, Veljkovic N, Leo E, Aluigi M, Borsi E, Galloni C, Iacobucci I, Barbieri E, Santucci MA. Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia. J Cell Biochem. 2012. 113(8):2765-74.
  4. Stojković L, Djurić T, Stanković A, Dinčić E, Stančić O, Veljković N, Alavantić D, Zivković M. The association of V249I and T280M fractalkine receptor haplotypes with disease course of multiple sclerosis. J Neuroimmunol. 2012. 245(1-2):87-92.

 

2011

 

  1. Veljkovic N, Glisic S, Perovic V, Veljkovic V. The role of long-range intermolecular interactions in discovery of new drugs. Expert Opin Drug Discov. 2011. 6(12):1263-70.
  2. Veljkovic M, Dopsaj V, Dopsaj M, Branch DR, Veljkovic N, Sakarellos-Daitsiotis MM, Veljkovic V, Glisic S, Colombatti A. Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy. PLoS One. 2011. 6(11):e28304.
  3. Veljkovic M, Branch DR, Dopsaj V, Veljkovic V, Veljkovic N, Glisic S, Colombatti A. Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?  Med Hypotheses. 2011. 77(3):404-8.
  4. Vasiljevic N, Veljkovic N, Kosec T, Ma XZ, Glisic S, Prljic J, Vujicic AD, Markovic L, Branch DR. A bioinformatics approach to identify natural autoantibodies from healthy blood donors' sera reactive with the HCV NS5A-derived peptide by immunoassay. Viral Immunol. 2011. 24(2):69-76.

 

2010

 

  1. Tintori C, Veljkovic N, Veljkovic V, Botta M. Computational studies of the interaction between the HIV-1 integrase tetramer and the cofactor LEDGF/p75: insights from molecular dynamics simulations and the informational spectrum method. Proteins. 2010. 78(16):3396-408.
  2. Veljkovic M, Dopsaj V, Stringer WW, Sakarellos-Daitsiotis M, Zevgiti S, Veljkovic V, Glisic S, Dopsaj M. Aerobic exercise training as a potential source of natural antibodies protective against human immunodeficiency virus-1. Scand J Med Sci Sports. 2010. 20(3):469-74.

 

Before 2010

 

  1. Veljkovic V, Veljkovic N, Muller CP, Müller S, Glisic S, Perovic V, Köhler H. Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control. BMC Struct Biol. 2009. 9:21.
  2. Veljkovic V, Niman HL, Glisic S, Veljkovic N, Perovic V, Muller CP. Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor. BMC Struct Biol. 2009. 9:62.
  3. Mancini M, Veljkovic N, Corradi V, Zuffa E, Corrado P, Pagnotta E, Martinelli G, Barbieri E, Santucci MA. 14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia. Traffic. 2009. 10(6):637-47.
  4. Veljkovic N, Glisic S, Prljic J, Perovic V, Botta M, Veljkovic V. Discovery of new therapeutic targets by the informational spectrum method. Curr Protein Pept Sci. 2008. 9(5):493-506.
  5. Mancini M, Zuffa E, Veljkovic N, Brusa G, Corrado P, Corradi V, Martinelli G, Barbieri E, Santucci MA. IPO-trimethylation of histone H3-lysine9 associated with P210 BCR-ABL tyrosine kinase of chronic myeloid leukaemia. Br J Haematol. 2008. 141(6):899-902.
  6. Veljkovic V, Veljkovic N, Glisic S, Ho MW. AIDS vaccine: efficacy, safety and ethics. Vaccine. 2008. 6;26(24):3072-7.
  7. Doliana R, Veljkovic V, Prljic J, Veljkovic N, De Lorenzo E, Mongiat M, Ligresti G, Marastoni S, Colombatti A. EMILINs interact with anthrax protective antigen and inhibit toxin action in vitro. Matrix Biol. 2008. 27(2):96-106.
  8. Glisic S, Arrigo P, Alavantic D, Perovic V, Prljic J, Veljkovic N. Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular disease. Proteins. 2008. 15;70(3):855-62.
  9. Mugnaini C, Rajamaki S, Tintori C, Corelli F, Massa S, Witvrouw M, Debyser Z, Veljkovic V, Botta M. Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies. Bioorg Med Chem Lett. 2007. 17(19):5370-3.
  10. Tintori C, Manetti F, Veljkovic N, Perovic V, Vercammen J, Hayes S, Massa S, Witvrouw M, Debyser Z, Veljkovic V, Botta M. Novel virtual screening protocol based on the combined use of molecular modeling and electron-ion interaction potential techniques to design HIV-1 integrase inhibitors. J Chem Inf Model. 2007. 47(4):1536-44.
  11. Metlas R, Srdic T, Veljkovic V. Anti-IgG antibodies from sera of healthy individuals neutralize HIV-1 primary isolates. Curr HIV Res. 2007. 5(2):261-5.
  12. Veljkovic V, Veljkovic N, Esté JA, Hüther A, Dietrich U. Application of the EIIP/ISM bioinformatics concept in development of new drugs. Curr Med Chem. 2007. 14(4):441-53.
  13. Veljkovic V, Mouscadet JF, Veljkovic N, Glisic S, Debyser Z. Simple criterion for selection of flavonoid compounds with anti-HIV activity. Bioorg Med Chem Lett. 2007. 17(5):1226-32.
  14. Djordjevic A, Veljkovic M, Antoni S, Sakarellos-Daitsiotis M, Krikorian D, Zevgiti S, Dietrich U, Veljkovic N, Branch DR. The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection. Curr HIV Res. 2007. 5(5):443-8.
  15. Raicevic S, Wright JV, Veljkovic V, Conca JL. Theoretical stability assessment of uranyl phosphates and apatites: selection of amendments for in situ remediation of uranium. Sci Total Environ. 2006. 355(1-3):13-24.
  16. Veljkovic N, Perovic V. In silico criterion for prediction of effects of p53 gene missense mutations on p53-Mdm2 feedback loop. Protein Pept Lett. 2006. 13(8):807-14.
  17. Veljkovic N, Branch DR, Metlas R, Prljic J, Manfredi R, Stringer WW, Veljkovic V. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease. J Clin Virol. 2004. 31 Suppl 1:S39-44.
  18. Veljkovic V, Prljic J, Veljkovic T. Safety and ethical consideration of AIDS vaccine. Int Rev Immunol. 2004. 23(5-6):465-86.
  19. Prljic J, Veljkovic N, Veljkovic V. Recombination property of the HIV-1 gp120 gene.  Int Rev Immunol. 2004. 23(5-6):447-54.
  20. Veljkovic V, Metlas R. Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease. Int Rev Immunol. 2004. 23(5-6):437-45.
  21. Metlas R, Veljkovic V. HIV-1 gp120 and immune network. Int Rev Immunol. 2004. 23(5-6):413-22.
  22. Veljkovic V, Veljkovic N, Metlas R. Molecular makeup of HIV-1 envelope protein. Int Rev Immunol. 2004. 23(5-6):383-411.
  23. Veljkovic V, Köhler H, Müller S. AIDS vaccine: state of the art at the beginning of the third millennium.  Int Rev Immunol. 2004. 23(5-6):369-81.
  24. Ivanović V, Demajo M, Todorović-Raković N, Nikolić-Vukosavljević D, Nesković-Konstantinović Z, Krtolica K, Veljković V, Prljić J, Dimitrijević B. Localization of recognition site between transforming growth factor-beta1 (TGF-beta1) and TGF beta receptor type II: possible implications in breast cancer. Med Hypotheses. 2004. 62(5):727-32.
  25. Veljkovic N, Branch DR, Metlas R, Prljic J, Vlahovicek K, Pongor S, Veljkovic V. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease. J Pept Res. 2003. 62(4):158-66.
  26. Veljkovic V, Müller S, Köhler H. AIDSVAX results: an important open question. Vaccine. 2003. 21(25-26):3528-9.
  27. Veljkovic V, Müller S, Köhler H. Does VaxGen hide the breakthrough infections? Lancet. 2003. 361(9370):1743-4.
  28. Veljkovic V, Metlas R, Köhler H, Urnovitz HB, Prljic J, Veljkovic N, Johnson E, Müller S. AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. Vaccine. 2001. 19(15-16):1855-62.
  29. Veljkovic V, Metlas R, Jevtovic D, Stringer WW. The role of passive immunization in hiv-positive patients : a case report. Chest. 2001. 120(2):662-6.
  30. Prljić J, Veljković N, Doliana R, Colombatti A, Johnson E, Metlas R, Veljković V. Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines. Vaccine. 1999. 17(11-12):1462-7.
  31. Metlas R, Trajkovic D, Srdic T, Veljkovic V, Colombatti A. Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures. J Acquir Immune Defic Syndr. 1999. 21(4):266-70.
  32. Metlas R, Trajkovic D, Srdic T, Veljkovic V, Colombatti A. Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera. AIDS Res Hum Retroviruses. 1999. 15(7):671-7.
  33. Prljić J, Veljković N, Doliana R, Colombatti A, Johnson E, Metlas R, Veljković V. Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines. Vaccine. 1999. 17(11-12):1462-7.
  34. Veljković V, Johnson E, Metlas R. Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120. Vaccine. 1997. 15(5):473-4.
  35. Metlas R, Skerl V, Veljković V, Pongor S. Further evidence for the relationship of HIV-1 gp120 V3 loops with Ig superfamily members: similarity with the putative CDR3 region of T-cell receptor delta-chains. Immunol Lett. 1995. 47(1-2):25-8.
  36. Metlas R, Veljković V. Does the HIV-1 manipulate immune network via gp120 immunoglobulin-like domain involving V3 loop? Vaccine. 1995. 13(4):355-9.
  37. Metlas R, Skerl V, Pongor S, Colombatti A, Veljković V. Reactivity of AIDS patient sera with a peptide derived from HIV type 1NY5 glycoprotein 120 V3 loop and consensus sequence of collagens. AIDS Res Hum Retroviruses. 1994. 10(11):1425-6.
  38. Metlas R, Skerl V, Veljkovic V, Colombatti A, Pongor S. Immunoglobulin-like domain of HIV-1 envelope glycoprotein gp120 encodes putative internal image of some common human proteins. Viral Immunol. 1994. 7(4):215-9.
  39. Veljkovic V, Metlas R. Potentially negative effects of AIDS vaccines based on recombinant viruses carrying HIV-1 derived envelope gene. A warning on AIDS vaccine development. Vaccine. 1993. 11(3):291-2.
  40. Veljkovic V, Metlas R, Raspopovic J, Pongor S. Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS. Biochem Biophys Res Commun. 1992. 189(2):705-10.
  41. Veljković V, Metlas R. HIV and idiotypic T-cell regulation: another view. Immunol Today. 1992. 13(1):38.
  42. Veljković V, Metlas R. Identification of immunoglobulin recombinant elements in human immunodeficiency virus type 1 envelope gene. Immunol Lett. 1992. 31(1):11-4.
  43. Metlas R, Veljkovic V, Paladini RD, Pongor S. Protein and DNA-sequence homologies between the V3-loop of human immunodeficiency virus type I envelope protein gp120 and immunoglobulin variable regions. Biochem Biophys Res Commun. 1991. 179(2):1056-62.
  44. Veljković V, Metlas R. Sequence similarity between human immunodeficiency virus type 1 envelope protein (gp120) and human proteins: a new hypothesis on protective antibody production. Immunol Lett. 1990. 26(2):193-5.
  45. Lalović D, Veljković V. The global average DNA base composition of coding regions may be determined by the electron-ion interaction potential. Biosystems. 1990. 23(4):311-6.
  46. Veljković V, Metlas R. Identification of nanopeptide from HTLV-III, ARV-2 and LAVBRU envelope gp120 determining binding to T4 cell surface protein. Cancer Biochem Biophys. 1988. 10(2):91-106.
  47. Veljković V, Cosić I.  A novel method of protein analysis for prediction of biological function: application to tumor toxins. Cancer Biochem Biophys. 1987. 9(2):139-48.
  48. Veljković V, Cosić I, Dimitrijević B, Lalović D. Is it possible to analyze DNA and protein sequences by the methods of digital signal processing? IEEE Trans Biomed Eng. 1985. 32(5):337-41.
  49. Vojvodic V, Veljkovic V, Cosic I, Lalovic D. Correlation between some physical parameters and alkaline hydrolysis rate constants of organophosphorous compounds. Arch Belg. 1984. Suppl:49-52.
  50. Veljković V, Vojvodić V. Theoretical possibilities of estimating the harmful effects of various chemicals on living organisms. Arh Hig Rada Toksikol. 1981. 32(4):311-9.
  51. Veljković V, Lalović DI. Correlation between the carcinogenicity of organic substances and their spectral characteristics. Experientia. 1978. 34(10):1342-3.
  52. Veljković V, Lalović DI. Simple theoretical criterion of chemical carcinogenicity. Experientia. 1977. 33(9):1228-9.
  53. Veljkovic V, Lalovic DI. Theoretical prediction of mutagenicity and carcinogenicity of chemical substances. Cancer Biochem Biophys. 1976. 1(6):295-8.